BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33096424)

  • 1. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
    Biterge Süt B
    Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection.
    Saitta C; Lanza M; Bertuccio A; Lazzara S; Navarra G; Raimondo G; Pollicino T
    Cancer Genet; 2015 Oct; 208(10):513-6. PubMed ID: 26341700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
    Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
    Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinomas with Concomitant Mutations of TERT, TP53, and CTNNB1: Is There a Role for Artificial Intelligence?
    Chillotti S; Maloberti T; Degiovanni A; Malvi D; D'Errico A; de Biase D; Vasuri F
    Crit Rev Oncog; 2023; 28(3):31-35. PubMed ID: 37968991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
    Huang X; Yang C; Wang J; Sun T; Xiong H
    Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.
    Xiao X; Mo H; Tu K
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107043. PubMed ID: 33039961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
    Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
    Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
    Hosny G; Farahat N; Tayel H; Hainaut P
    Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and histological correlations in liver cancer.
    Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
    J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
    J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.